CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors

Exclusion criteria

• . Asymptomatic untreated brain metastases; symptomatic central nervous system (CNS) metastases or carcinomatous meningitis; or other evidence of uncontrolled CNS/meningeal metastases that are considered unsuitable for enrollment by the investigator.
• . Presence of clinically significant cardiovascular, pulmonary, neurological, or systemic disease at baseline that may increase study participation risk or interfere with safety assessments.
• . Presence of severe chronic or active infection at baseline, including:
• . Active hepatitis B (HBsAg positive with HBV DNA \> ULN);
• . Active hepatitis C (anti-HCV positive with detectable HCV RNA);
• . Known history of or positive test for human immunodeficiency virus (HIV);
• . Systemic anti-infective therapy required within 4 weeks prior to first administration, including hospitalization for infectious complications, bacteremia, severe pneumonia, or active tuberculosis.
• . History of active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis) or receipt of long-term systemic corticosteroids (prednisone \> 10 mg/day or equivalent) or other immunosuppressive agents within 4 weeks prior to first administration.